These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24244586)

  • 1. Comparative efficacy of Lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials.
    Ford N; Shubber Z; Hill A; Vitoria M; Doherty M; Mills EJ; Gray A
    PLoS One; 2013; 8(11):e79981. PubMed ID: 24244586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
    Sax PE; Tierney C; Collier AC; Fischl MA; Mollan K; Peeples L; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Ha B; Woodward WC; Koletar SL; Johnson VA; Geiseler PJ; Daar ES;
    N Engl J Med; 2009 Dec; 361(23):2230-40. PubMed ID: 19952143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virological efficacy of abacavir: systematic review and meta-analysis.
    Cruciani M; Mengoli C; Malena M; Serpelloni G; Parisi SG; Moyle G; Bosco O
    J Antimicrob Chemother; 2014 Dec; 69(12):3169-80. PubMed ID: 25074854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV.
    Benson CA; van der Horst C; Lamarca A; Haas DW; McDonald CK; Steinhart CR; Rublein J; Quinn JB; Mondou E; Rousseau F;
    AIDS; 2004 Nov; 18(17):2269-76. PubMed ID: 15577539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
    Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
    Mira JA; López-Cortés LF; Barreiro P; Tural C; Torres-Tortosa M; de Los Santos Gil I; Martín-Rico P; Ríos-Villegas MJ; Hernández-Burruezo JJ; Merino D; López-Ruz MA; Rivero A; Muñoz L; González-Serrano M; Collado A; Macías J; Viciana P; Soriano V; Pineda JA
    J Antimicrob Chemother; 2008 Dec; 62(6):1365-73. PubMed ID: 18854330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
    Martínez E; Arranz JA; Podzamczer D; Loncá M; Sanz J; Barragán P; Ribera E; Knobel H; Roca V; Gutiérrez F; Blanco JL; Mallolas J; Llibre JM; Clotet B; Dalmau D; Segura F; Arribas JR; Cosín J; Barrufet P; Casas E; Ferrer E; Curran A; González A; Pich J; Cruceta A; Arnaiz JA; Miró JM; Gatell JM;
    J Acquir Immune Defic Syndr; 2009 Jul; 51(3):290-7. PubMed ID: 19398921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emtricitabine: new preparation. An antiretroviral very similar to lamivudine.
    Prescrire Int; 2005 Apr; 14(76):54-6. PubMed ID: 15875341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
    Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
    Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy.
    Humphreys EH; Chang LW; Harris J
    Cochrane Database Syst Rev; 2010 Jun; (6):CD006517. PubMed ID: 20556768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: systematic review and meta-analysis.
    Chowers M; Gottesman BS; Leibovici L; Schapiro JM; Paul M
    Eur J Clin Microbiol Infect Dis; 2010 Jul; 29(7):779-86. PubMed ID: 20449621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presence of lamivudine or emtricitabine is associated with reduced emergence of nonnucleoside reverse transcriptase inhibitor mutations in an efavirenz-based intermittent antiretroviral treatment regimen.
    Trancart S; Charreau I; Marchou B; Bocquentin M; Molina JM; Izopet J; Tangre P; Aboulker JP; Taburet AM;
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1655-7. PubMed ID: 22203586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.
    Raffi F; Rachlis A; Brinson C; Arasteh K; Górgolas M; Brennan C; Pappa K; Almond S; Granier C; Nichols WG; Cuffe RL; Eron J; Walmsley S
    AIDS; 2015 Jan; 29(2):167-74. PubMed ID: 25387312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
    Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
    JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.
    Post FA; Moyle GJ; Stellbrink HJ; Domingo P; Podzamczer D; Fisher M; Norden AG; Cavassini M; Rieger A; Khuong-Josses MA; Branco T; Pearce HC; Givens N; Vavro C; Lim ML
    J Acquir Immune Defic Syndr; 2010 Sep; 55(1):49-57. PubMed ID: 20431394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml.
    Nishijima T; Komatsu H; Teruya K; Tanuma J; Tsukada K; Gatanaga H; Kikuchi Y; Oka S
    AIDS; 2013 Mar; 27(5):839-42. PubMed ID: 23719354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
    Sánchez-de la Rosa R; Herrera L; Moreno S
    Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
    Brogan AJ; Talbird SE; Cohen C
    Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.